个人简介

Personal Profile

王常珺，现任北京协和医院乳腺外科副主任医师、教学秘书。2007年获协和医大临床医学(八年制)博士。 2012年赴香港中文大学威尔斯亲王医院（Prince Of Wales Hospital)接受香港外科医学院及英国皇家爱丁堡外科学院(HKICBSC)培训；2013年兼任北京协和医院外科教学秘书，负责本科生及研究生外科理论及手术技能教学工作；2013年入选北京协和医院“百人计划”；2015-2016年国家留学基金委资助公派至美国加州大学旧金山分校（UCSF）乳腺肿瘤中心及UCSF Helen Diller综合癌症中心进修乳腺癌诊治临床技能；2019年度赴美国斯坦福大学（Stanford Healthcare）交流学习。曾承担药物生物化学国家重点实验室开放基金（2019014），并参与我科所承担的参与国家“十一五”支撑项目（2006BAI02A09）及北京市科委科技计划重大项目（D090507043409009）。现承担北京医师协会乳腺疾病专家委员会副秘书长、中国老年学学会老年肿瘤专业委员会理事等多项学会任职。现任Frontiers in Oncology、 Medical Science Monitor、Scientific Reports.SCI杂志审稿专家。参与发表SCI文章51篇，其中第一作者/共通一作发表SCI论文21篇，累计IF 80.948分。附代表性成果： 1. Wang C, Zhou Y, Mao F, Lin Y, Sun Q. Breast Cancer Screening in Denmark. Ann Intern Med. 2017 Oct 3;167(7):522. doi: 10.7326/L17-0268. 2. Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang X, Sun Q, Li C. Efficacy and safety profile of histone deacetylases inhibitors for metastatic breast cancer: A Meta-analysis. Front Oncol. 2022 in press. doi: 10.1038/s41598-020-61648-1. 3. Wang CJ, Xu Y, Lin Y, Zhu HJ, Zhou YD, Mao F, Zhang XH, Huang X, Zhong Y, Sun Q, Li CG. Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis. Front Oncol. 2020 Nov 9;10:592998. doi: 10.3389/fonc.2020.592998. 4. Wang C, Xu Y, Lin Y, Zhou Y, Mao F, Zhang X, Shen S, Zhang Y, Sun Q. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction. Breast. 2022 Jun;63:61-70. doi: 10.1016/j.breast.2022.03.007. 5. Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang X, Zhou X, Cao X, Sun Q. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis. Breast Cancer. 2022 Mar;29(2):314-323. doi: 10.1007/s12282-021-01312-2. 6. Wang C, Zhou Y, Lin Y, Mao F, Guan J, Zhang X, Shen S, Wang X, Zhang Y, Pan B, Zhong Y, Peng L, Cao X, Yao R, Zhou X, Xu C, Xu Y, Sun Q. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2？+？early breast cancer (PHAEDRA). BMC Cancer. 2022 Mar 14;22(1):269. doi: 10.1186/s12885-022-09346-1. 7. Wang C, Chen Z, Zhou Y, Huang W, Zhu H, Mao F, Lin Y, Zhang Y, Guan J, Cao X, Sun Q. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes. Gland Surg. 2021 Mar;10(3):943-952. doi: 10.21037/gs-20-7628. Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan J, Zhang X, Shen S, Huang X, Chen C, Yao R, Zhao J, Sun Q. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. BMC Cancer. 2020 Jul 13;20(1):653. doi: 10.1186/s12885-020-07143-29. Wang C, Zhou Y, Huang W, Chen Z, Zhu H, Mao F, Lin Y, Zhang X, Shen S, Zhong Y, Huang X, Chen C, Sun Q. The impact of pre-existed and SERM-induced non-alcoholic fatty liver disease on breast cancer survival: a meta-analysis. J Cancer. 2020 May 18;11(15):4597-4604. doi: 10.7150/jca.44872. 10. Wang C, Zhou Y, Zhu H, Huang W, Chen Z, Mao F, Lin Y, Zhang X, Shen S, Zhong Y, Li Y, Sun Q. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer? Cancer Med. 2018 Nov;7(11):5420-5430. doi: 10.1002/cam4.1785. Epub 2018 Oct 1.

团队简介

Team Profile

待补充更新